Normal and pathologic erythropoiesis in adults: from gene regulation to targeted treatment concepts


Disclosures: P.V. received honoraria from Novartis and Celgene and research grants from Novartis and Celgene. I.T. received honoraria from Novartis and Kymab and a research grant from Kymab. U.G. received honoraria from Celgene, Novartis, and Janssen and research support from Celgene and Novartis. R.S. received honoraria from Novartis and Celgene and research support from Celgene. W.F. received honoraria from Alexion and Novartis. M.P. received honoraria from Novartis und Celgene. W.R.S. received honoraria from Novartis, Celgene, Teva, Ratiopharm and Deciphera, and a research grant from Meda Pharma. K.G. received honoraria from Novartis, Celgene, Teva, Incyte, Pfizer, and BMS. U.J. received honoraria and research funding from Novartis and Roche. O.H. received research grants from Novartis and Celgene. The authors declare that they have no other conflicts of interest in this study.

Contributions: All authors contributed equally by participating in pre-conference and post-conference discussion-rounds, by participating actively in the working conference, by formulating consensus statements, by writing parts of the manuscript, and by reviewing the final paper. All authors approved the final version of the document.